{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:43:12Z","timestamp":1791308592491,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd007621","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T00:00:00Z","timestamp":1317772800000}}],"reference-count":148,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007621.pub2","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T12:29:08Z","timestamp":1317212948000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Natalizumab for relapsing remitting multiple sclerosis"],"prefix":"10.1002","volume":"2011","author":[{"given":"Eugenio","family":"Pucci","sequence":"first","affiliation":[{"name":"ASUR Marche - Zona Territoriale 9; U.O. Neurologia - Ospedale di Macerata; Via Santa Lucia, 3 Macerata Italy 62100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Giuliani","sequence":"additional","affiliation":[{"name":"ASUR Marche - Zona Territoriale 9; U.O. Neurologia - Ospedale di Macerata; Via Santa Lucia, 3 Macerata Italy 62100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Solari","sequence":"additional","affiliation":[{"name":"Fondazione I.R.C.C.S. - Neurological Institute Carlo Besta; Neuroepidemiology Unit; Via Celoria 11 Milan Italy 20133"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Simi","sequence":"additional","affiliation":[{"name":"Past Senior Researcher of Institute of Clinical Physiology; Via Rosini, 15 Pisa Italy 56124"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Minozzi","sequence":"additional","affiliation":[{"name":"ASL RM\/E; Department of Epidemiology; Via di Santa Costanza, 53 Rome Italy 00198"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Di Pietrantonj","sequence":"additional","affiliation":[{"name":"Azienda Sanitaria Locale ASL AL; Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field; Via Venezia 6 Alessandria Piemonte Italy 15100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Galea","sequence":"additional","affiliation":[{"name":"University of Southampton; Division of Clinical Neurosciences, School of Medicine; Mailpoint 806, Level D Southampton General Hospital Southampton Hampshire UK SO16 6YD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,5]]},"reference":[{"key":"10.1002\/14651858.CD007621.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1212\/01.wnl.0000259521.14704.a8","article-title":"Natalizumab reduces visual loss in patients with relapsing multiple sclerosis","volume":"68","author":"Balcer","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000242629.66372","article-title":"Infusion-related hypersensitivity reactions during natalizumab treatment","volume":"67","author":"Phillips","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD007621.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A Randomized placebo-controlled trial of Nataluzimab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"NEJM"},{"issue":"4","key":"10.1002\/14651858.CD007621.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","article-title":"Health related quality of life in multiple sclerosis: effects of natalizumab","volume":"62","author":"Rudick","year":"2007","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1212\/01.wnl.0000259521.14704.a8","article-title":"Natalizumab reduces visual loss in patients with relapsing multiple sclerosis","volume":"68","author":"Balcer","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","article-title":"Health related quality of life in multiple sclerosis: effects of natalizumab","volume":"62","author":"Rudick","year":"2007","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"NEJM"},{"issue":"3","key":"10.1002\/14651858.CD007621.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.53.3.466","article-title":"The effect of anti-[alpha]4 integrin antibody on brain lesion activity in MS","volume":"53","author":"Tubridy","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of nataluzimab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"NEJM"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/135245850000600305","article-title":"New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis","volume":"6","author":"Balcer","year":"2000","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0014|cit14","unstructured":"Belachew S Phan-Ba R Bartholom\u00e9 E Delvaux V Hansen I Calay P Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis European Journal of Neurology 10.1111\/j.1468-1331.2010.03112.x"},{"issue":"12","key":"10.1002\/14651858.CD007621.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1177\/1352458509347154","article-title":"Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?","volume":"15","author":"Bergamaschi","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007621.pub2-BIB0016|cit16","first-page":"A356","article-title":"Natalizumab use in two French Multiple Sclerosis Centers: the incidence of hypersensitivity reactions based on premedication practices","volume":"72","author":"Berger","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0017|cit17","unstructured":"Biogen Idec Elan Pharmaceuticals Tysabri\u00ae (natalizumab) Advisory Committee Briefing Document www.fda.gov\/ohrms\/dockets\/ac\/06\/briefing\/2006-4208B1_02_01Biogenbriefingmaterial.pdf"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0018|cit18","unstructured":"Biogen Idec Inc Genentech USA Inc Rituxan\u00ae Full Prescribing Information - USA"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0019|cit19","unstructured":"Bozic C Belcher G Kooijmans M Kim R Lynn F Panzara MA The Safety of Natalizumab in Patients With Relapsing Multiple. Update from TOUCH TM and TYGRIS. Poster No P06.095 Proceedings of the 59th Annual Meeting of the American Academy of Neurology; 2007 Apr 28 - May 5; Boston (MA) 2007"},{"issue":"3","key":"10.1002\/14651858.CD007621.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ana.21835","article-title":"Natalizumab and central nervous system lymphoma: no clear association","volume":"66","author":"Bozic","year":"2009","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0021|cit21","unstructured":"Bozic C Belcher G Kim R Hyde R Lynn F Kooijmans-Coutinho\u00a0 M Natalizumab in Patients with Relapsing Multiple Sclerosis: Updated Utilization and Safety Results including TOUCH\u00a0 and TYGRIS. Abstracts S11.005. American Academy of Neurology 61st Annual Meeting; 2009 Apr 25 - May 2; Seattle (WA) 2009"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of antinatalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-1331.2006.01273.x","article-title":"Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis","volume":"13","author":"Caon","year":"2006","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/1352458508092810","article-title":"Early relapses after the first dose of natalizumab in active multiple sclerosis patients","volume":"14","author":"Centonze","year":"2008","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD007621.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurology"},{"issue":"Supl 3","key":"10.1002\/14651858.CD007621.pub2-BIB0026|cit26","first-page":"A357","article-title":"Case report of recurrent pericarditis due to natalizumab treatment with positive re-challenging test","volume":"72","author":"Cohen","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1212\/WNL.0b013e3181dad567","article-title":"Giant urticaria and persistent neutralizing antibodies after the first natalizumab infusion","volume":"74","author":"Cohen","year":"2010","journal-title":"Neurology"},{"issue":"S4","key":"10.1002\/14651858.CD007621.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1177\/1352458509347129","article-title":"Clinical efficacy and benefit of natalizumab","volume":"15","author":"Coyle PK Jeffery","year":"2009","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD007621.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF03256144","article-title":"Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis\u00a0","volume":"7","author":"Earnshaw","year":"2009","journal-title":"Applied Health Economics and Health Policy"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1212\/01.wnl.0000313034.46883.16","article-title":"Disability as an outcome in MS clinical trials","volume":"71","author":"Ebers","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0032|cit32","unstructured":"Center for Drug Evaluation and Research. Reviewer: Bryan WW Clinical Review BLA 125104\/0 Tysabri (natalizumab) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/125104s000_Natalizumab_Medr_P1.pdf"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0033|cit33","unstructured":"Center for Drug Evaluation and Research. Office of Pharmacoepidemiology and Statistical Science. Office of Biostatistics Statistical review and evaluation. Natalizumab. NDA\/serial number 125104(0) http:\/\/www.fdable.com\/wiki\/images\/7\/70\/Statistical_review_natalizumab.pdf"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1474-4422(02)00008-X","article-title":"Predictive value of MRI findings in multiple sclerosis","volume":"1","author":"Filippi","year":"2002","journal-title":"The Lancet Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0035|cit35","unstructured":"Francis G Panzara M Tysabri (Dear Healthcare Professional Letter) Biogen ldec and Elan Pharmaceuticals"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000127972","article-title":"Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison","volume":"60","author":"Freedman","year":"2008","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jnnp.69.6.728","article-title":"Community services in multiple sclerosis: still a matter of chance","volume":"69","author":"Freeman","year":"2000","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD007621.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis: the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"NEJM"},{"issue":"2","key":"10.1002\/14651858.CD007621.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2008.09.019","article-title":"An unusual complication of immunosuppression in myasthenia gravis: Progressive multifocal leukoencephalopathy","volume":"19","author":"Gedizlioglu","year":"2009","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD007621.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.59.6.909","article-title":"Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS","volume":"59","author":"Ghalie","year":"2002","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007621.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","article-title":"Safety and efficacy of natalizumab in children with multiple sclerosis","volume":"75","author":"Ghezzi","year":"2010","journal-title":"Neurology"},{"issue":"275(1-2)","key":"10.1002\/14651858.CD007621.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2008.07.026","article-title":"Participation in medical decision-making: Attitudes of Italians with multiple sclerosis","volume":"15","author":"Giordano","year":"2008","journal-title":"Journal of Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD007621.pub2-BIB0043|cit43","first-page":"184","article-title":"Treating Multiple Sclerosis in the Natalizumab Era: Risks, Benefits, Clinical Decision Making, and a Comparison Between North American and European Union Practices","volume":"4","author":"Giovannoni","year":"2007","journal-title":"Reviews in Neurological Diseases"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jneuroim.2007.04.006","article-title":"Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies","volume":"187","author":"Gold","year":"2007","journal-title":"Journal of Neuroimmunology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1212\/01.wnl.0000320512.21919.d2","article-title":"Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"71","author":"Goodin","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007621.pub2-BIB0046|cit46","first-page":"S8\u2013S13","article-title":"Disease-modifying therapy in multiple Sclerosis Update and clinical implications","volume":"71","author":"Goodin","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2466\/pms.1977.44.2.367","article-title":"Paced Auditory Serial-Addition Task: a measure of recovery from concussion","volume":"44","author":"Gronwall","year":"1977","journal-title":"Perceptual and Motor Skills"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0b013e3181cef810","article-title":"Severe cutaneous candida infection during natalizumab therapy in multiple sclerosis","volume":"74","author":"Gutwinski","year":"2010","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1352458508100036","article-title":"Early relapses after the first dose of natalizumab in active multiple sclerosis","volume":"15","author":"Haartsen","year":"2009","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s00415-008-0883-x.","article-title":"Fulminant tumefactive multiple sclerosis: Therapeutic implications of histopathology","volume":"255","author":"Haupts","year":"2008","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-Cell Depletion with Rituximab in Relapsing? Remitting Multiple Sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"NEJM"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1191\/1352458504ms1112oa","article-title":"Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis","volume":"10","author":"Heesen","year":"2004","journal-title":"Multiple Sclerosis"},{"issue":"12","key":"10.1002\/14651858.CD007621.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1177\/1352458510379819","article-title":"Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists","volume":"16","author":"Heesen","year":"2010","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD007621.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archneur.65.5.656","article-title":"Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy","volume":"65","author":"Hellwig","year":"2008","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0057|cit57","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collboration, 2008."},{"key":"10.1002\/14651858.CD007621.pub2-BIB0058|cit58","unstructured":"Horga A Castill\u00f3 J R\u00edo J Tintor\u00e9 M Edo MC P\u00e9erez-Miralles F Effectiveness and safety of natalizumab in patients with relapsing multiple sclerosis: report of three-year experience in a multiple sclerosis centre, Catalonia. P841. Proceedings of 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) & 15th Annual Conference of Rehabilitation in MS (RIMS); 2010 Oct 13-16; Gothenburg, Sweden 2010"},{"issue":"2","key":"10.1002\/14651858.CD007621.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/tcrm.2007.3.2.259","article-title":"Natalizumab: A new treatment for relapsing remitting multiple sclerosis","volume":"3","author":"Hutchinson","year":"2007","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-009-5183-6","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0061|cit61","unstructured":"ICH Expert Working Group In: Clinical Safety Data Management Definition and Standards for Expidet Reporting. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 1994 Oct 27 http:\/\/www.private.ich.org\/cache\/compo\/475-272-1.html#E2A"},{"issue":"10","key":"10.1002\/14651858.CD007621.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00415-009-5200-9","article-title":"Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis","volume":"256","author":"Ismail","year":"2009","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0063|cit63","unstructured":"Jones D Ionete C Recurrent autoimmune thrombocytopenia after exposure to interferon beta-1a and natalizumab World Congress on Treatment and Research in Multiple Sclerosis, the first joint meeting of ACTRIMS (the Americas Committee on Treatment and Research in Multiple Sclerosis) and its counterparts in Europe and Latin America: ECTRIMS and LACTRIMS; 2008 Sept 17-20; Montr\u00e9al 2008"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","article-title":"Natalizumab treatment for multiple sclerosis: recommendations for patients selection and monitoring","volume":"6","author":"Kappos","year":"2007","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007621.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-5728(94)00165-K","article-title":"A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis","volume":"58","author":"Kent","year":"1995","journal-title":"Journal of Neuroimmunology"},{"issue":"4","key":"10.1002\/14651858.CD007621.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1352458508101322","article-title":"Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies","volume":"15","author":"Killestein","year":"2009","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ana.22074","article-title":"Natalizumab drug holiday in multiple sclerosis: Poorly tolerated","volume":"68","author":"Killestein","year":"2010","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1212\/WNL.0b013e3181b9c8f7","article-title":"The present efficacy of multiple sclerosis therapeutics. Is the new 66% just the old 33%?","volume":"73","author":"Klawiter","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"NEJM"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00019052-200406000-00019","article-title":"New insights into progressive multifocal\u00a0 leukoencephalopathy","volume":"17","author":"Koralnik","year":"2004","journal-title":"Current Opinion in Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007621.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1191\/1352458505ms1117oa","article-title":"Evaluation of the Modified Fatigue Impact Scale in four different European countries","volume":"11","author":"Kos","year":"2005","journal-title":"Multiple Sclerosis"},{"issue":"9","key":"10.1002\/14651858.CD007621.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/archneur.64.9.1331","article-title":"Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies","volume":"64","author":"Krumbholz","year":"2007","journal-title":"Archives of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD007621.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"NEJM"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0075|cit75","unstructured":"Laroni A Bedognetti M Uccelli A Capello E Mancardi GL Association of melanoma and natalizumab therapy in the Italian MS population: a second case report Neurological Sciences"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1086\/368194","article-title":"Cryptosporidium species: new insights and old challenges","volume":"36","author":"Leav","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007621.pub2-BIB0077|cit77","first-page":"A203","article-title":"Natalizumab for stabilization of Susac syndrome","volume":"72","author":"Lee","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis:Results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1750-3639.1996.tb00854.x","article-title":"Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis","volume":"6","author":"Lucchinetti","year":"1996","journal-title":"Brain Pathology"},{"issue":"3","key":"10.1002\/14651858.CD007621.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1191\/1352458504ms1019rr","article-title":"The pathogenesis of multiple sclerosis: is it really a primary inflammatory process?","volume":"10","author":"Maggs","year":"2004","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0081|cit81","unstructured":"Mancardi GL Tedeschi G Amato MP D'Alessandro R Drago F Milanese C Three years of experience: the Italian registry and safety data update Neurological Sciences"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"499\u2013509","DOI":"10.1016\/S1474-4422(02)00223-5","article-title":"Inflammation in multiple sclerosis: the good, the bad, and the complex","volume":"1","author":"Martino","year":"2002","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007621.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD007621.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of Natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-134-8-200104170-00011","article-title":"The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials","volume":"134","author":"Moher","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007621.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/ar2373","article-title":"What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs","volume":"10","author":"Moore","year":"2008","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0304-3940(92)90883-9","article-title":"Detection of JC virus in the brains of aged patients without progressive multifocal leukoencephalopathy by the polymerase chain reaction and Southern hybridization analysis","volume":"141","author":"Mori","year":"1992","journal-title":"Neuroscience Letters"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMc0706103","article-title":"Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis","volume":"358","author":"Mullen","year":"2008","journal-title":"NEJM"},{"issue":"5","key":"10.1002\/14651858.CD007621.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis","volume":"59","author":"Niino","year":"2006","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life. The remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0092|cit92","unstructured":"O'Connor\u00a0 PW Goodman AD Kappos L Lublin FD Polman CH Rudick RA Updated efficacy and safety of natalizumab in patients who participated in the STRATA study Proceedings of 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) & 15th Annual Conference of Rehabilitation in MS (RIMS); 2010 Oct 13-16; Gothenburg, Sweden 2010"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1212\/01.WNL.0000128136.79044.D6","article-title":"Randomized multicenter trial of natalizumab in acute MS relapses. Clinical and MRI effects","volume":"62","author":"O'Connor\u00a0","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","article-title":"Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study","volume":"16","author":"Oturai","year":"2009","journal-title":"European Journal of Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007621.pub2-BIB0095|cit95","first-page":"A317","article-title":"Autoimmune haemolytic anemia under treatment with natalizumab","volume":"72","author":"Outteryck","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD007621.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00415-009-5294-0","article-title":"Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice","volume":"257","author":"Outteryck","year":"2010","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD007621.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1297-319X(03)00062-9","article-title":"JC virus leukoencephalopathy complicating Wegener's granulomatosis","volume":"70","author":"Pagnoux","year":"2003","journal-title":"Joint Bone Spine"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","article-title":"Randomized, comparative study of interferon \u03b2-1a treatment regimens in MS. The EVIDENCE Trial","volume":"59","author":"Panitch","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0099|cit99","unstructured":"Piehl F Holm\u00e9n C Hillert J Olsson T Swedish natalizumab (Tysabri) multiple sclerosis surveillance study Neurolocial Sciences"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1212\/01.wnl.0000255797.19050.e8","article-title":"Implications for treatment. Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow?","volume":"68","author":"Pittock","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald' criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007621.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD007621.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2009.06.004","article-title":"Multiple sclerosis associated fatigue during natalizumab treatment","volume":"285","author":"Putzki","year":"2009","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD007621.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000276400","article-title":"Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland","volume":"63","author":"Putzki","year":"2010","journal-title":"European Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007621.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1468-1331.2009.02728.x","article-title":"Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries","volume":"17","author":"Putzki","year":"2010","journal-title":"European Journal of Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007621.pub2-BIB0106|cit106","first-page":"A134","article-title":"Natalizumab in the therapy of multifocal motoric neuropathy (MMN): first case report","volume":"72","author":"Raji","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for Multiple Sclerosis","volume":"356","author":"Ransohoff\u00a0","year":"2007","journal-title":"NEJM"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0108|cit108","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"11","key":"10.1002\/14651858.CD007621.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/1352458509107011","article-title":"Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis","volume":"15","author":"Rinaldi","year":"2009","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1167\/iovs.02-1100","article-title":"How sensitive to clinical change are ETDRS and logMAR visual acuity measurements?","volume":"44","author":"Rosser","year":"2003","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/1352458502ms845oa","article-title":"The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials","volume":"8","author":"Rudick","year":"2002","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: a4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Review Neurotherapeutics"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0113|cit113","unstructured":"Sangalli F Moiola L Annovazzi P Bucello S Radaelli M Ghezzi A Three years efficacy and tolerability of natalizumab treatment. P896. Proceedings of 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) & 15th Annual Conference of Rehabilitation in MS (RIMS); 2010 Oct 13-16; Gothenburg, Sweden 2010"},{"issue":"4","key":"10.1002\/14651858.CD007621.pub2-BIB0114|cit114","first-page":"222","article-title":"Progressive multifocal leukoencephalopathy as a cause of neurologic symptoms in Sharp syndrome","volume":"50","author":"Schneider","year":"1991","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical Evidence of BiasDimensions of Methodological Quality Associated With Estimates of treatment Effects in Controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21782","article-title":"Primary central nervous system lymphoma in a patient treated with natalizumab","volume":"66","author":"Schweikert","year":"2009","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/archneur.62.5.785","article-title":"Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis. The EVIDENCE Study","volume":"62","author":"Schwid","year":"2005","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0118|cit118","unstructured":"Sharief MK The impact of change in interferon beta-1a dose regimen (30mcg qw to 44mcg tiw) in patients with relapsing MS - cross-over results from the EVIDENCE study. ENS Meeting; 2003 June; Istanbul, Turkey 2003"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","article-title":"A safety and pharmacokinetic study of intravenous natalizumab in patients with MS","volume":"52","author":"Sheremata","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD007621.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1352458506074689","article-title":"Communicating the diagnosis of multiple sclerosis - a qualitative study","volume":"13","author":"Solari","year":"2007","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007621.pub2-BIB0121|cit121","first-page":"A84","article-title":"Early effects of natalizumab on patient reported fatigue and cognitive function","volume":"72","author":"Stephenson","year":"2009","journal-title":"Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD007621.pub2-BIB0122|cit122","first-page":"S2","article-title":"Incidence rate of acute myeloid leukaemia and related mortality in Italian Multiple Sclerosis patients treated with mitoxantrone","volume":"31","author":"Straffi","year":"2010","journal-title":"Neurological Sciences"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"357\u201364","DOI":"10.1212\/01.wnl.0000319648.65173.7a","article-title":"Quantitative risk-benefit analysis of natalizumab","volume":"71","author":"Thompson","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"NEJM"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/01.wnl.0000194259.90286.fe","article-title":"Disability progression in multiple sclerosis is slower than previously reported","volume":"66","author":"Tremlett","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2004\u201315","DOI":"10.1212\/WNL.0b013e3181e3973f","article-title":"New perspectives in the natural history of multiple sclerosis","volume":"74","author":"Tremlett","year":"2010","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0129|cit129","unstructured":"US Food Drug Administration Natalizumab (marketed as TYSABRI): Serious liver injury http:\/\/www.fda.gov\/cder\/dsn\/2008_spring\/postmarketing.htm#natalizumab"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0130|cit130","unstructured":"US Food Drug Administration Information on Natalizumab (marketed as Tysabri) http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm107198.htm"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0131|cit131","unstructured":"US Food Drug Administration Risk of Progressive Multifocal Leukoencephalopathy (PML) with the use of Tysabri (natalizumab) FDA Drug Safety Communication http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders,"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohns disease","volume":"353","author":"Assche","year":"2005","journal-title":"NEJM"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1212\/WNL.55.9.1341","article-title":"Management of multiple sclerosis across managed care and fee-for-service systems","volume":"55","author":"Vickrey","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD007621.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1191\/1352458504ms1084oa","article-title":"An open-label safety and drug interaction study of natalizumab (Antegren) incombination with interferon-beta (Avonex) in patients with multiple sclerosis","volume":"10","author":"Vollmer","year":"2004","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS SF-36 Short-Form Health Survey (SF-36). Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0136|cit136","volume-title":"SF-36 Health Survey: Manual and interpretation guide","author":"Ware","year":"1993"},{"issue":"8","key":"10.1002\/14651858.CD007621.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","article-title":"Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?","volume":"67","author":"Warnke","year":"2010","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"Natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","article-title":"Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab","volume":"361","author":"Wenning","year":"2009","journal-title":"NEJM"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","article-title":"Natalizumab dosage suspension: Are we helping or hurting?","volume":"68","author":"West","year":"2010","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/jvi.66.10.5726-5734.1992","article-title":"JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy","volume":"66","author":"White","year":"1992","journal-title":"Journal of Virology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/41.7.826","article-title":"Progressive multifocal leukencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus","volume":"41","author":"White","year":"2002","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1756285608101861","article-title":"Natalizumab in the treatment of multiple sclerosis","volume":"2","author":"Yaldizli","year":"2009","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"6364","key":"10.1002\/14651858.CD007621.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"issue":"9","key":"10.1002\/14651858.CD007621.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"NEJM"},{"issue":"17","key":"10.1002\/14651858.CD007621.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1212\/WNL.0b013e3181bd114f","article-title":"Ocular toxoplasmosis during natalizumab treatment","volume":"73","author":"Zecca","year":"2009","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007621.pub2-BIB0147|cit147","first-page":"A241","article-title":"Extensive erosive dermatitis associated with hypereosinophilia under natalizumab treatment","volume":"72","author":"Zephir","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007621.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0404.2006.00627.x","article-title":"Glatiramer acetate in treatment-na\u00efve and prior interferon-\u00df-1b-treated multiple sclerosis patients","volume":"113","author":"Zwibel","year":"2006","journal-title":"Acta neurologica Scandinavica"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007621.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:48:20Z","timestamp":1787647700000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007621.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,10,5]]},"references-count":148,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007621.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,5]]}}}